Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

PF614 · PRF06104

Small molecule · Agonist of mu opioid receptor (OPRM1) · developed by Ensysce Biosciences

Phase 3 Most advanced trial
ENSC Developer
3 Registered trials

What is PF614?

PF614 is an oxycodone prodrug being studied for acute postoperative and acute pain. As a prodrug, it is converted in the body to oxycodone, which acts as a mu opioid receptor agonist.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PRF06104, Oxycodone prodrug
Drug type
Small molecule
Targets
mu opioid receptor (OPRM1)
Mechanism
Agonist of mu opioid receptor (OPRM1)
Developer
Ensysce Biosciences (ENSC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06602271 Phase 3 Postoperative Pain, Acute Recruiting ENSC
NCT06629402 Phase 2 Acute Pain Completed ENSC
NCT05090280 Phase 1 Pharmacokinetics Completed ENSC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Postoperative Pain, AcuteAcute PainPharmacokinetics

Other drugs acting on OPRM1

Methadone FDA approved Morphine FDA approved Nalbuphine FDA approved Naloxone FDA approved Naltrexone FDA approved Oxycodone FDA approved

More from Ensysce Biosciences

Nafamostat Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ENSC page.

Follow ENSC, the company behind PF614

See ENSC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ENSC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.